Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

References

• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• CassonRJChidlowGWoodJPCrowstonJGGoldbergIDefinition of glaucoma: clinical and experimental conceptsClin Experiment Ophthalmol201240434134922356435
   PubMed Web of Science ®Google Scholar
• PetersDBengtssonBHeijlAFactors associated with lifetime risk of open-angle glaucoma blindnessActa Ophthalmol Epub2013710
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study GroupComparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressuresAm J Ophthalmol199812644874979780093
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology Glaucoma PanelPreferred Practice Pattern^® Guidelines. Primary Open-Angle GlaucomaSan Francisco, CAAmerican Academy of Ophthalmology2010
   Google Scholar
• The AGIS InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol2000130442944011024415
   PubMed Web of Science ®Google Scholar
• WebersCABeckersHJNuijtsRMSchoutenJSPharmacological management of primary open-angle glaucoma: second-line options and beyondDrugs Aging200825972975918729546
   PubMed Web of Science ®Google Scholar
• RealiniTA history of glaucoma pharmacologyOptom Vis Sci2011881363821131876
   PubMed Web of Science ®Google Scholar
• NguyenQHThe role of prostaglandin analogues in the treatment of glaucoma in the 21st centuryInt Ophthalmol Clin2004442152715087728
   PubMedGoogle Scholar
• WatanabeKChiouGCAction mechanism of timolol to lower the intraocular pressure in rabbitsOphthalmic Res19831531601676314218
   PubMed Web of Science ®Google Scholar
• MincioneFScozzafavaASupuranCTThe development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agentsCurr Top Med Chem20077984985417504129
   PubMed Web of Science ®Google Scholar
• TorisCBGabeltBTKaufmanPLUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reductionSurv Ophthalmol200853Suppl 1S107S12019038618
   PubMed Web of Science ®Google Scholar
• ArthurSCantorLBUpdate on the role of alpha-agonists in glaucoma managementExp Eye Res201193327128321524649
   PubMed Web of Science ®Google Scholar
• European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edBern, SwitzerlandEuropean Glaucoma Society Available at: http://www.eugs.org/eng/EGS_guidelines.aspAccessed January 24, 2014
   Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• ReardonGKotakSSchwartzGFObjective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic reviewPatient Prefer Adherence2011544146322003282
   PubMed Web of Science ®Google Scholar
• AriasASchargelKUssaFCanutMIRoblesAYSanchezBMPatient persistence with first-line antiglaucomatous monotherapyClin Ophthalmol2010426126720463793
   PubMedGoogle Scholar
• NordstromBLFriedmanDSMozaffariEQuigleyHAWalkerAMPersistence and adherence with topical glaucoma therapyAm J Ophthalmol2005140459860616226511
   PubMed Web of Science ®Google Scholar
• WilenskyJFiscellaRGCarlsonAMMorrisLSWaltJMeasurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims dataAm J Ophthalmol20061411 SupplS28S3316389058
   PubMed Web of Science ®Google Scholar
• HigginbothamEJHansenJDavisEJWaltJGGuckianAGlaucoma medication persistence with a fixed combination versus multiple bottlesCurr Med Res Opin200925102543254719731993
   PubMed Web of Science ®Google Scholar
• SchwartzGBurkCBennettTPatelVDAdherence and persistence with glaucoma therapy: brimonidine/timolol versus dorzolamide/timolol and various two-bottle combinationsJ Clin Exp Ophthalmol20123816
   Google Scholar
• RossiGCPasinettiGMScudellerLRadaelliRBianchiPEDo adherence rates and glaucomatous visual field progression correlate?Eur J Ophthalmol201121441041421140373
   PubMed Web of Science ®Google Scholar
• DjafariFLeskMRHarasymowyczPJDesjardinsDLachaineJDeterminants of adherence to glaucoma medical therapy in a long-term patient populationJ Glaucoma200918323824319295380
   PubMed Web of Science ®Google Scholar
• FriedmanDSOkekeCOJampelHDRisk factors for poor adherence to eyedrops in electronically monitored patients with glaucomaOphthalmology200911661097110519376591
   PubMed Web of Science ®Google Scholar
• OkekeCOQuigleyHAJampelHDAdherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid studyOphthalmology2009116219119919084273
   PubMed Web of Science ®Google Scholar
• ReesGLeongOCrowstonJGLamoureuxELIntentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucomaOphthalmology2010117590390820153902
   PubMed Web of Science ®Google Scholar
• SleathBRobinALCovertDByrdJETudorGSvarstadBPatient-reported behavior and problems in using glaucoma medicationsOphthalmology2006113343143616458967
   PubMed Web of Science ®Google Scholar
• UngCZhangEAlfaroTGlaucoma severity and medication adherence in a county hospital populationOphthalmology201312061150115723453512
   PubMed Web of Science ®Google Scholar
• VandenbroeckSDe GeestSDobbelsFFieuwsSStalmansIZeyenTPrevalence and correlates of self-reported nonadherence with eye drop treatment: the Belgian Compliance Study in Ophthalmology (BCSO)J Glaucoma201120741442121048510
   PubMed Web of Science ®Google Scholar
• HongSKangSYYoonJUKangUSeongGJKimCYDrug attitude and adherence to anti-glaucoma medicationYonsei Med J201051226126920191020
   PubMed Web of Science ®Google Scholar
• OlthoffCMHoevenaarsJGvan den BorneBWWebersCASchoutenJSPrevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patientsGraefes Arch Clin Exp Ophthalmol2009247223524318802720
   PubMed Web of Science ®Google Scholar
• LoonSCJinJJin GohMThe relationship between quality of life and adherence to medication in glaucoma patients in SingaporeJ Glaucoma Epub20131116
   Web of Science ®Google Scholar
• ReesGChongXLCheungCYBeliefs and adherence to glaucoma treatment: a comparison of patients from diverse culturesJ Glaucoma Epub2013131
   Web of Science ®Google Scholar
• BullerAJConnellBSpencerAFCompliance: clear communication’s criticalBr J Ophthalmol20058910137016170136
   PubMed Web of Science ®Google Scholar
• DreerLEGirkinCMansbergerSLDeterminants of medication adherence to topical glaucoma therapyJ Glaucoma201221423424021623223
   PubMed Web of Science ®Google Scholar
• KholdebarinRCampbellRJJinYPBuysYMMulticenter study of compliance and drop administration in glaucomaCan J Ophthalmol200843445446118711461
   PubMed Web of Science ®Google Scholar
• NordmannJPBaudouinCRenardJPMeasurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: a surveyClin Ophthalmol2010473173920689790
   PubMedGoogle Scholar
• ForsmanEKivelaTVestiELifetime visual disability in open-angle glaucoma and ocular hypertensionJ Glaucoma200716331331917438426
   PubMed Web of Science ®Google Scholar
• VorwerkCThelenUBuchholzPKimmichFTreatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practiceCurr Med Res Opin20082451295130118366862
   PubMed Web of Science ®Google Scholar
• FriedmanDSHahnSRGelbLDoctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency StudyOphthalmology20081158132013271327.e1e318321582
   PubMed Web of Science ®Google Scholar
• RobinALNovackGDCovertDWCrockettRSMarcicTSAdherence in glaucoma: objective measurements of once-daily and adjunctive medication useAm J Ophthalmol2007144453354017686450
   PubMed Web of Science ®Google Scholar
• TsaiJCMcClureCARamosSESchlundtDGPichertJWCompliance barriers in glaucoma: a systematic classificationJ Glaucoma200312539339814520147
   PubMed Web of Science ®Google Scholar
• RobinALCovertDDoes adjunctive glaucoma therapy affect adherence to the initial primary therapy?Ophthalmology2005112586386815878067
   PubMed Web of Science ®Google Scholar
• ChraiSSMakoidMCEriksenSPRobinsonJRDrop size and initial dosing frequency problems of topically applied ophthalmic drugsJ Pharm Sci19746333333384820359
   PubMed Web of Science ®Google Scholar
• BullerAHerculesBLShould patients choose their own eyedrops?Acta Ophthalmol Scand200684115015116445459
   PubMedGoogle Scholar
• LiangHBrignole-BaudouinFPaulyARianchoLBaudouinCPolyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface studyAdv Ther201128431132521424577
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
   PubMed Web of Science ®Google Scholar
• HigginbothamEJConsiderations in glaucoma therapy: fixed combinations versus their component medicationsClin Ophthalmol201041920169043
   PubMedGoogle Scholar
• HommerAThygesenJFerrerasAA European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucomaEur J Ophthalmol200818577878618850558
   PubMed Web of Science ®Google Scholar
• InoueKSetogawaAHigaRMoriyamaRWakakuraMTomitaGOcular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from beta-blockers and prostaglandin analogsClin Ophthalmol2012623123522347794
   PubMedGoogle Scholar
• InoueKOkayamaRHigaRSawadaHWakakuraMTomitaGOcular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combinationJ Ocul Pharmacol Ther201127658158722011049
   PubMed Web of Science ®Google Scholar
• KitazawaYSmithPSasakiNKotakeSBaeKIwamotoYTravoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacyEye (Lond)20112591161116921701528
   PubMed Web of Science ®Google Scholar
• KatzGDubinerHSamplesJVoldSSallKThree-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%JAMA Ophthalmol2013131672473023579344
   PubMed Web of Science ®Google Scholar
• NguyenQHMcMenemyMGRealiniTWhitsonJTGoodeSMPhase III randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%J Ocul Pharmacol Ther201329329029723425430
   PubMed Web of Science ®Google Scholar
• RealiniTNguyenQHKatzGDubinerHFixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase III studiesEye (Lond)201327784184723640612
   PubMed Web of Science ®Google Scholar
• WhitsonJTRealiniTNguyenQHMcMenemyMGGoodeSMSix-month results from a phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertensionClin Ophthalmol201371053106023766627
   PubMedGoogle Scholar
• LeskeMCHeijlAHusseinMFactors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma TrialArch Ophthalmol20031211485612523884
   PubMedGoogle Scholar
• QuarantaLKatsanosARussoARivaI24-hour intraocular pressure and ocular perfusion pressure in glaucomaSurv Ophthalmol2013581264123217586
   PubMed Web of Science ®Google Scholar
• KonstasAGQuarantaLYanDBTwenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucomaEye (Lond)2012261808721960068
   PubMed Web of Science ®Google Scholar
• LiuJHMedeirosFASlightJRWeinrebRNComparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapyOphthalmology2009116344945419157559
   PubMed Web of Science ®Google Scholar
• IshikawaMYoshitomiTEffects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patientsClin Ophthalmol2009349350019750124
   PubMedGoogle Scholar
• van der ValkRWebersCASchoutenJSZeegersMPHendrikseFPrinsMHIntraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trialsOphthalmology200511271177118515921747
   PubMed Web of Science ®Google Scholar
• ChengJWChengSWGaoLDLuGCWeiRLIntraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysisPLoS ONE201279e4507923028770
   PubMed Web of Science ®Google Scholar
• BoyleJEGhoshKGieserDKAdamsonsIAA randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study GroupOphthalmology199810510194519519787368
   PubMed Web of Science ®Google Scholar
• BrandtJDCantorLBKatzLJBimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma200817321121618414107
   PubMed Web of Science ®Google Scholar
• CravenERWaltersTRWilliamsRBrimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertensionJ Ocul Pharmacol Ther200521433734816117698
   PubMed Web of Science ®Google Scholar
• HigginbothamEJFeldmanRStilesMDubinerHFixed Combination Investigative GroupLatanoprost and timolol combination therapy vs monotherapy: one-year randomized trialArch Ophthalmol2002120791592212096962
   PubMed Web of Science ®Google Scholar
• HigginbothamEJOlanderKWKimEEFixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked studyArch Ophthalmol2010128216517220142538
   PubMedGoogle Scholar
• HughesBABacharachJCravenERA three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertensionJ Glaucoma200514539239916148589
   PubMed Web of Science ®Google Scholar
• HutzelmannJOwensSSheddenAAdamsonsIVargasEComparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study GroupBr J Ophthalmol19988211124912539924327
   PubMed Web of Science ®Google Scholar
• PalmbergPKimEEKwokKKTresslerCSCanada and United States Fixed Combination Latanoprost/Timolol Study GroupA 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapyEur J Ophthalmol201020470871820099236
   PubMed Web of Science ®Google Scholar
• PfeifferNEuropean Latanoprost Fixed Combination Study GroupA comparison of the fixed combination of latanoprost and timolol with its individual componentsGraefes Arch Clin Exp Ophthalmol20022401189389912486510
   PubMed Web of Science ®Google Scholar
• SherwoodMBCravenERChouCTwice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trialArch Ophthalmol200612491230123816966616
   PubMedGoogle Scholar
• StrohmaierKSnyderEDuBinerHAdamsonsIThe efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study GroupOphthalmology199810510193619449787367
   PubMed Web of Science ®Google Scholar
• KabackMScoperSVArzenoGIntraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%Ophthalmology2008115101728173418538406
   PubMed Web of Science ®Google Scholar
• DiestelhorstMLarssonLIEuropean Latanoprost Fixed Combination Study GroupA 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertensionBr J Ophthalmol200488219920314736774
   PubMed Web of Science ®Google Scholar
• JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol200717334134917534814
   PubMed Web of Science ®Google Scholar
• KuppensEVde JongCAStolwijkTRde KeizerRJvan BestJAEffect of timolol with and without preservative on the basal tear turnover in glaucomaBr J Ophthalmol19957943393427742279
   PubMed Web of Science ®Google Scholar
• QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther201329438238923231442
   PubMed Web of Science ®Google Scholar
• SchumanJSClinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertensionSurv Ophthalmol199641Suppl 1S27S378970247
   PubMed Web of Science ®Google Scholar
• MelamedSDavidROngoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group IIClin Ther200022110311110688394
   PubMed Web of Science ®Google Scholar
• QuarantaLGandolfoFTuranoREffects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucomaInvest Ophthalmol Vis Sci20064772917292316799034
   PubMed Web of Science ®Google Scholar
• BonomiLMarchiniGMarraffaMBernardiPMorbioRVarottoAVascular risk factors for primary open angle glaucoma: the Egna-Neumarkt StudyOphthalmology200010771287129310889099
   PubMed Web of Science ®Google Scholar
• HeijlABengtssonBOskarsdottirSEPrevalence and severity of undetected manifest glaucoma: results from the early manifest glaucoma trial screeningOphthalmology201312081541154523631945
   PubMed Web of Science ®Google Scholar
• SchumanJSEffects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2Ophthalmology200010761171117710857839
   PubMed Web of Science ®Google Scholar
• BauerKBrunner-FerberFDistlerathLMAssessment of systemic effects of different ophthalmic beta-blockers in healthy volunteersClin Pharmacol Ther19914966586641676358
   PubMed Web of Science ®Google Scholar
• JavittJCSchiffmanRMClinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group IJ Glaucoma20009322423410877373
   PubMed Web of Science ®Google Scholar
• KassMAGordonMOHoffMRTopical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trialArch Ophthalmol198910711159015982818278
   PubMedGoogle Scholar
• UusitaloHKahonenMRopoAImproved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucomaGraefes Arch Clin Exp Ophthalmol2006244111491149616628416
   PubMed Web of Science ®Google Scholar
• WaldockASnapeJGrahamCMEffects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patientsBr J Ophthalmol200084771071310873979
   PubMed Web of Science ®Google Scholar
• McCartyCAMukeshBNKitchnerTEIntraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research ProjectJ Glaucoma200817537237718703947
   PubMed Web of Science ®Google Scholar
• HommerARole of fixed combinations in the management of open-angle glaucomaExpert Rev Pharmacoecon Outcomes Res2011111919921351861
   PubMed Web of Science ®Google Scholar
• DicksonMPlauschinatCACompliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapyAm J Cardiovasc Drugs200881455018303937
   PubMed Web of Science ®Google Scholar
• TaylorAAShoheiberOAdherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapyCongest Heart Fail20039632433214688505
   PubMedGoogle Scholar